Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASP Isotopes's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASP Isotopes's regulatory disclosures and financial reporting.
Moore Duncan, a director of ASP Isotopes Inc. (ASPI), reported the sale of 75,000 shares on 08/29/2025 at a weighted average price of $9.2831. After the sale he beneficially owned 994,553 shares. The filing states the sale included shares sold to satisfy income tax liabilities arising from the vesting of a previously granted restricted stock award for 200,000 shares. The weighted-average price represents multiple trades executed between $8.95 and $10.20. The Form 4 was signed by an attorney-in-fact on 09/03/2025. This disclosure records an insider disposition tied to tax withholding for a stock award.
ASP Isotopes Inc. filed a current report to disclose that it issued a letter to shareholders dated September 2, 2025. The company is furnishing this shareholder letter as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is intended to provide broadly available information to the market. The filing specifies that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other SEC documents if specifically referenced.
ASP Isotopes Inc. (ASPI) filed a Form 144 notifying the proposed sale of 75,000 shares of its common stock through Independent Trading Group (ITG) on the NASDAQ with an aggregate market value of $789,750. The filer acquired 200,000 shares as a restricted stock award on August 16, 2023, paid by equity compensation on that date. The approximate date of sale is listed as August 29, 2025. The filing reports no securities sold during the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
ASP Isotopes Inc. reports it will host a corporate access event for South African investors ahead of an anticipated secondary listing of its common stock on the Johannesburg Stock Exchange, with trading on the JSE Main Board expected to begin on August 27, 2025, while retaining its primary Nasdaq listing and not raising new capital in connection with the listing. The company provides operational updates across several isotope programs in Pretoria, including commercial production of Silicon-28, where first enriched samples were shipped to a U.S. customer in August 2025, and Ytterbium-176, where enrichment has reached up to 92.4% and the first fully enriched batch is expected by the end of August 2025 with shipments to follow.
The Ytterbium-176 plant is running in batch mode and has had a 3–4 week delay in equipment for semi-continuous processing, shifting that transition to late third or early fourth quarter 2025 from prior late August guidance. The company has obtained initial permits to import controlled laser equipment for Nickel-64, Gadolinium-160 and Zinc-68 and is accelerating enrichment facility plans. Its Carbon plant, originally prepared for Carbon-14, is now enriching Carbon-12 to 99.99% for a U.S. customer, with first commercial product now expected in September 2025 after a regulatory-related delay, and demand for Carbon-12 is described as significantly higher than for Carbon-14.
ASP Isotopes reiterates expectations to initiate a spin-out of its Quantum Leap Enrichment subsidiary as a standalone public company during the second half of 2025 and continues to anticipate closing the Renergen acquisition in the third quarter of 2025, in each case subject to required approvals and consents. Company, QLE and Renergen representatives also plan to participate in a RedChip conference call on August 28, 2025.
ASP Isotopes Inc. reported that it and its subsidiary, Quantum Leap Energy LLC, entered into a Memorandum of Understanding with Fermi America for a U.S. joint venture. The parties intend to collaborate on the research, development and construction of an advanced nuclear fuel research and production facility at the planned 11GW HyperGrid Campus in Carson County, Texas.
The company disclosed this arrangement through a press release dated August 15, 2025, which is attached as an exhibit and incorporated by reference, except for three specified paragraphs.
AWM Investment Company, Inc. reports beneficial ownership of 3,931,186 shares of ASP Isotopes Inc., representing 4.3% of the outstanding common stock. AWM states it is the investment adviser to five funds and holds sole voting and sole dispositive power over the shares allocated across those funds, with individual fund holdings disclosed in the filing. The disclosure identifies the funds by name and provides a per‑fund share breakdown, making the ownership position transparent.
Filing statements indicate the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing also names the controlling principals associated with the funds and confirms there is no shared voting or dispositive power reported.
AWM Investment Company, Inc. reports beneficial ownership of 619,874 shares of ASP Isotopes Inc. common stock, representing 6.9% of the class. The shares are held by Special Situations Private Equity Fund, L.P. (SSPE), for which AWM acts as investment adviser, and AWM states it holds sole voting and sole dispositive power over these shares.
The filing identifies David M. Greenhouse and Adam C. Stettner as members of MG Advisers, L.L.C., the general partner of SSPE, and as controlling principals of AWM. The report includes a certification that the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control.
ASP Isotopes Inc. (ASPI) filed an 8-K disclosing Item 8.01 – Other Events. The company announced, via the attached 8-Aug-2025 press release, its expected commencement of a dual listing on the Johannesburg Stock Exchange (JSE). Management believes the additional listing will complement the existing Nasdaq quotation under ticker ASPI. No financial statements, guidance, or transactional details were provided in the filing. Exhibit 99.1 contains the full release (except its 6th-7th paragraphs), while Exhibit 104 supplies the Inline XBRL cover page data.
The dual-listing plan may widen ASPI’s investor base, improve liquidity and brand visibility in South Africa, but will also subject the company to JSE regulatory requirements and incremental compliance costs. No timeline, capital raise, or pricing information was included.
ASP Isotopes Inc. (ASPI) disclosed a material definitive agreement on 28 Jul 2025. The company is investing $5 million to acquire 2 million Series Seed-1 Preferred shares of privately held IsoBio, Inc. at $2.50 per share.
- Strategic fit: IsoBio develops antibody-isotope conjugate radiotherapeutics; ASPI gains exposure to oncology applications that can expand its isotope value chain.
- Governance rights: ASPI secures 1 of 3 IsoBio board seats, broad veto rights over major corporate actions, and weighted-average anti-dilution protection.
- Conversion terms: Preferred is convertible 1:1 into IsoBio common at $2.50, automatically upon ≥ $50 m IPO or 2/3 holder consent; shares are non-redeemable.
- Ancillary agreements: Investors’ Rights, ROFR/Co-Sale, and Voting pacts grant ASPI demand registration, first-offer rights, and opportunity to buy stock before key holders sell.
- Related-party aspect: ASPI CEO Paul Mann and director Todd Wider are also designated IsoBio directors, creating potential conflicts but ensuring oversight.
- Next steps: Management will discuss IsoBio on a 30 Jul 2025 investor call; slide deck filed as Exhibit 99.1.
No immediate financial results were provided; cash outflow and future dilution depend on IsoBio’s capital needs and exit timeline.
ASP Isotopes Inc. (Nasdaq: ASPI) filed an 8-K dated 28 Jul 2025 to disclose a joint press release with IsoBio, Inc. announcing IsoBio’s initial Series Seed financing. The funds will be used to advance IsoBio’s proprietary Antibody-Isotope Conjugate platform (AICs TM) aimed at oncology indications.
The companies will host an investor webcast on 30 Jul 2025 at 10:00 a.m. ET to discuss the collaboration. No dollar amount, valuation or ownership details were provided in the filing. The press release is furnished as Exhibit 99.1 (excluding its fifth and sixth paragraphs). No other items, financial statements or pro-forma data accompanied the report.
For ASPI, the disclosure signals strategic expansion into radiopharma-enabled biologics but carries limited immediate financial visibility. The filing is informational and does not amend prior guidance or trigger accounting changes.